- recruitingPhase I and Phase II (Integrated)- First administration to humans
A first-in-human, open-label, multicenter Phase I/II study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1)
This early-stage study tests a new experimental cancer drug called ANV600. Doctors want to see if it is safe and works well against advanced solid tumours. It will be tested on its own and together with pembrolizumab, an existing immunotherapy medicine, in adults aged 18 and over.
Germany · France · Belgium - authorisedHuman Pharmacology (Phase I)- First administration to humans
A PHASE 1/1B, OPEN-LABEL, MULTICENTER, FIRST-IN-HUMAN DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF VVD-159642 AS A SINGLE AGENT AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
This study is testing a new medicine, VVD-159642, for people with advanced solid cancers. It's an early-stage trial looking at how safe the medicine is, what side effects it might have, and if it helps fight cancer. It will be given alone and with other treatments.
Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1 study to look at RP-6306 in combination with FOLFIRI as a treatment for Advanced Solid Tumours
Doctors are testing a new treatment called RP-6306 with standard chemotherapy (FOLFIRI) for people with advanced cancers. This early-stage study checks if the combination is safe and helps patients. It's for adults, and you won't know which treatment you get.
Spain - recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors
This study is testing a new drug, BMS-986408, alone and with existing cancer drugs, nivolumab and ipilimumab, for advanced solid tumours. It aims to see how safe the new drug is and what side effects it might cause, as well as how well it works.
France · Spain - recruitingPHASE1, PHASE2
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
This study is testing a new drug, UCB4594, for advanced cancers. It's the first time it’s being used in people. Researchers want to find the safest dose, understand side effects, and see if it can shrink certain tumours by helping the body's immune system.
United Kingdom - recruiting
Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response and Resistance in Patients With Advanced Solid Tumours Through Sample Analysis
This study looks at changes in cancer cells to understand why some treatments work better for certain people with advanced solid cancers. It aims to help doctors choose the best treatments and develop more personal care.
United Kingdom